Showing results (211-220 of 224) with videos related to
Sort By:
Pageof 23
Biotechnology Healthcare|April 6, 2012
Payers tightening management of specialty therapiesKirk McConnell, Melinda C HarenBiotechnology Healthcare|April 6, 2012
Rethinking comparative effectiveness researchBiotechnology Healthcare|April 6, 2012
FTC Versus Congress: The Biosimilars DebateKathleen Carr, Thomas WintnerBiotechnology Healthcare|April 6, 2012
IOM Likes Its CER List; Others Might if It Suits ThemFrank DiamondBiotechnology Healthcare|April 6, 2012
Payer perspectives on federally funded comparative effectiveness researchSarah CollinsBiotechnology Healthcare|April 6, 2012
Managing the immunomodulatorsBiotechnology Healthcare|April 6, 2012
The value of observational cohort studies for cancer drugsDavid R SpigelBiotechnology Healthcare|April 6, 2012
Why Bigger Is Better For Controlling Oncology Spend: It offers less competition - perhaps - but can be a boon for evidence-based pathway initiativesJohn CarrollPageof 23